"The most bizarre we've ever seen." That's how Jefferies & Co. analyst Corey Davis described the FDA advisory panel meeting earlier this month on Daxas (roflumilast), the drug candidate for chronic obstructive pulmonary disease from Forest Laboratories Inc. and Nycomed GmbH.
Some of the world's best scientific brains were gearing up for the American Academy of Neurology meeting this week in Toronto, and among the hoped-for data to tumble out of sessions are details of Biogen Idec Inc.'s approach to using an iffy but promising method of weeding out likely PML cases from multiple sclerosis patients.
Salix Pharmaceuticals Inc.'s path forward should become clear shortly with the approved antibiotic Xifaxan in its third potential, and much-coveted, indication: irritable bowel syndrome. (BioWorld Today)
With last week's federal ruling that invalidated Myriad Genetics Inc.'s patent claims on BRCA1 and BRCA2 genes, all eyes are on the appeals court, even as pundits continue to speculate what an ultimate, irrevocable decision either way might mean.
Spring's onset brings pollen, allergies and - for many - asthma, which for as much as 35 percent of patients falls into the category of "uncontrolled." That's the high end of the estimated subset of about 22 million adult asthmatics in the U.S., and about the same number overseas. Corticosteroids aren't getting the job done, but which new target can, in a crowded market worth about $12.7 billion worldwide, according to GlobalData?
